查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1610030

非酒精性脂肪性肝炎临床试验市场规模、份额和趋势分析报告：按阶段、研究设计、地区和细分市场预测，2025-2030

Non-alcoholic Steatohepatitis Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

非酒精性脂肪性肝炎临床试验市场成长与趋势

Grand View Research, Inc.最新报告显示，预计到2030年，全球非酒精性脂肪性肝炎临床试验市场规模将达到41.4亿美元，2025年至2030年复合年增长率为6.26%。医疗成本上升、肥胖病例和非酒精性脂肪性肝炎（NASH）的流行是推动该市场成长的因素。 COVID-19 大流行停止了 NASH 患者新药临床试验的招募，但人们转向了虚拟就诊等替代资料收集方法。非酒精性脂肪性肝炎是脂肪肝，会导致肝臟疤痕和损伤。

目前尚无 FDA核准的NASH治疗方法，在极端情况下，疾病可能会发展到患者需要进行肝臟移植的程度。 NASH 与糖尿病一样，与肥胖和高糖饮食有关。一些製药公司正在测试糖尿病治疗是否可以帮助 NASH 患者。然而，COVID-19 大流行对 NASH 临床试验的各个要素提出了挑战，从患者招募到 IP 剂量、安全监测和资料完整性。由于临床研究监测仪无法移动，远端电子监测是传统现场监测的可行替代方案。监测员可以透过纸本邮件、电子邮件（允许直接存取电子健康记录）或远端监测系统从研究中心接收资讯。

12 月，FDA 发布指南，鼓励製药业开发和验证改进的生物标记物，用于 NASH 的诊断和进展。在许多方面，与普遍缺乏对 NASH 的认识相比，切片检查的障碍非常重要。这就是为什么製药公司正在投资创新技术（例如各种诊断影像技术）来减轻患者负担，并利用积极的资料来鼓励接受这些进展作为临床试验中适当的终点标誌物，关键是要说服 FDA。

非酒精性脂肪性肝炎临床试验市场报告亮点

  • III 期试验占据市场主导地位，2024 年占总销售份额的 54.3%。 III 期试验对于在提交监管部门核准之前确认新治疗方法的有效性和安全性至关重要。
  • 2024 年，由于越来越关注新型治疗性介入的评估，介入测试领域占据了市场主导地位。此外，越来越多的研发研究测试 NASH 的候选药物，包括单一疗法和联合治疗。
  • 2024年，北美非酒精性脂肪性肝炎临床试验市场占据主导地位，份额为48.9%。该地区的成长归功于其先进的医疗保健系统、庞大的患者群体和强大的研究基础设施。
  • 亚太地区非酒精性脂肪性肝炎临床试验市场预计在预测期内将以最高复合年增长率成长。这种增长是由糖尿病和肥胖等代谢疾病的日益普及所推动的。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章非酒精性脂肪性肝炎临床试验市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章非酒精性脂肪性肝炎临床试验市场：阶段、估计与趋势分析

  • 细分仪表板
  • 全球非酒精性脂肪性肝炎临床试验市场、阶段与变异分析
  • 非酒精性脂肪性肝炎临床试验规模及趋势分析（分阶段，2018-2030年）
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第五章非酒精性脂肪性肝炎临床试验市场：研究设计、估算与趋势分析

  • 细分仪表板
  • 全球非酒精性脂肪性肝炎临床试验市场、研究设计变异分析
  • 非酒精性脂肪性肝炎临床试验规模与趋势分析（依研究设计，2018-2030）
  • 干预研究
  • 观察性研究
  • 扩大访问研究

第六章 非酒精性脂肪性肝炎临床试验市场：区域估计与趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 公司分类
  • 2024 年企业市场分析
  • 公司简介
    • Pfizer Inc.
    • Novartis AG
    • Icon Plc
    • Laboratory Corporation of America
    • AbbVie Inc.
    • Cadila Healthcare Ltd.
    • Takeda Pharmaceuticals
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Gilead Sciences Inc.
Product Code: GVR-4-68039-911-4

Non-alcoholic Steatohepatitis Clinical Trials Market Growth & Trends:

The global non-alcoholic steatohepatitis clinical trials market size is expected to reach USD 4.14 billion by 2030, registering a CAGR of 6.26% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising healthcare expenditure, cases of obesity, and prevalence of non-alcoholic steatohepatitis (NASH) are the factors driving the growth of this market. Due to the COVID-19 pandemic, enrollment in new drug clinical trials for NASH patients was halted, but people shifted to alternate means of data collecting methods, like virtual visits. Non-alcoholic Steatohepatitis is a fatty liver disease that causes scarring and damage to the liver.

NASH has no FDA-approved treatment and can proceed to the point where patients need a liver transplant in extreme situations. NASH, like diabetes, is linked to obesity and a high-sugar diet. Some pharmaceutical companies are testing whether diabetes drugs could help NASH patients. However, the COVID-19 pandemic has thrown a wrench into every element of NASH clinical trials, from patient recruiting to IP administration and safety monitoring to data integrity. As clinical research monitors are not allowed to travel, remote electronic monitoring is a viable alternative to traditional on-site monitoring. Monitors could receive information from research locations by paper mail, e-mail (allowing direct access to electronic medical records), or remote monitoring systems.

In December, the FDA issued guidance urging the pharmaceutical sector to develop and confirm improved biomarkers for the diagnosis and progression of NASH. In many aspects, getting past the biopsy barrier is significant compared to a lack of general awareness of NASH, that's why it is critical for pharmaceutical companies to invest in innovations (such as a variety of imaging techniques) to alleviate this patient burden, and then persuade the FDA with positive data to accept those advancements as appropriate end-point markers for clinical trials.

Non-alcoholic Steatohepatitis Clinical Trials Market Report Highlights:

  • The phase III segment dominated the market, accounting for 54.3% of the total revenue share in 2024. Phase III trials are essential for confirming the efficacy and safety of new therapies before they can be submitted for regulatory approval.
  • The interventional studies segment dominated the market in 2024 owing to an increasing focus on evaluating new therapeutic interventions. Moreover, growing research and development studies to test novel drug candidates, including both monotherapies and combination therapies for NASH.
  • North America non-alcoholic steatohepatitis clinical trials market dominated and accounted for a 48.9% share in 2024. The growth in the region is attributed to the region's advanced healthcare system, large patient population, and strong research infrastructure.
  • The non-alcoholic steatohepatitis clinical trials market in Asia Pacific is expected to grow at the highest CAGR over the forecast period. The growth can be attributed to the increasing prevalence of metabolic disorders, such as diabetes and obesity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Non-alcoholic Steatohepatitis Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Pharmaceutical R&D Investment
      • 3.2.1.2. Rising Diabetic Population & Obesity
      • 3.2.1.3. Rising Healthcare Expenditure
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of Awareness
      • 3.2.2.2. Barriers to Enrolment
      • 3.2.2.3. Lethargic Drug Approval Process
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Non-alcoholic Steatohepatitis Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Non-alcoholic steatohepatitis clinical trials Market; Phase Movement Analysis
  • 4.3. Global Non-alcoholic Steatohepatitis Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Non-alcoholic Steatohepatitis Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Non-alcoholic Steatohepatitis Clinical Trials Market; Study Design Movement Analysis
  • 5.3. Global Non-alcoholic steatohepatitis clinical trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
  • 5.4. Interventional Studies
    • 5.4.1. Interventional studies market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Observational Studies
    • 5.5.1. Observational studies market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Expanded Access Studies
    • 5.6.1. Expanded access studies market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Non-alcoholic Steatohepatitis Clinical Trials Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. North America
    • 6.3.1. North America Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Competitive scenario
      • 6.3.2.3. Regulatory framework
      • 6.3.2.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Competitive scenario
      • 6.3.3.3. Regulatory framework
      • 6.3.3.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Competitive scenario
      • 6.3.4.3. Regulatory framework
      • 6.3.4.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Competitive scenario
      • 6.4.2.3. Regulatory framework
      • 6.4.2.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Competitive scenario
      • 6.4.3.3. Regulatory framework
      • 6.4.3.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Competitive scenario
      • 6.4.4.3. Regulatory framework
      • 6.4.4.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Competitive scenario
      • 6.4.5.3. Regulatory framework
      • 6.4.5.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Competitive scenario
      • 6.4.6.3. Regulatory framework
      • 6.4.6.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Competitive scenario
      • 6.4.7.3. Regulatory framework
      • 6.4.7.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Competitive scenario
      • 6.4.8.3. Regulatory framework
      • 6.4.8.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key country dynamics
      • 6.4.9.2. Competitive scenario
      • 6.4.9.3. Regulatory framework
      • 6.4.9.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Competitive scenario
      • 6.5.2.3. Regulatory framework
      • 6.5.2.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Competitive scenario
      • 6.5.3.3. Regulatory framework
      • 6.5.3.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Competitive scenario
      • 6.5.4.3. Regulatory framework
      • 6.5.4.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Competitive scenario
      • 6.5.5.3. Regulatory framework
      • 6.5.5.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Competitive scenario
      • 6.5.6.3. Regulatory framework
      • 6.5.6.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Competitive scenario
      • 6.5.7.3. Regulatory framework
      • 6.5.7.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework
      • 6.6.2.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Competitive scenario
      • 6.6.3.3. Regulatory framework
      • 6.6.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. MEA Market Estimates and Forecasts 2018 - 2030 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework
      • 6.7.2.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework
      • 6.7.3.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework
      • 6.7.4.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Competitive scenario
      • 6.7.5.3. Regulatory framework
      • 6.7.5.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Position Analysis, 2024
  • 7.3. Company Profiles
    • 7.3.1. Pfizer Inc.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Service benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Novartis AG
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Service benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Icon Plc
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Service benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Laboratory Corporation of America
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Service benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. AbbVie Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Service benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Cadila Healthcare Ltd.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Service benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Takeda Pharmaceuticals
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Service benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Eli Lilly and Company
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Service benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Novo Nordisk A/S
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Service benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Gilead Sciences Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Service benchmarking
      • 7.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 4 Global Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 5 Global Non-alcoholic Steatohepatitis Clinical Trials, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Non-alcoholic Steatohepatitis Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 8 North America Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 9 U.S. Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 10 U.S. Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 11 Canada Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 12 Canada Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 13 Mexico Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 14 Mexico Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 15 UK Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 16 UK Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 17 Germany Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Germany Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 19 France Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 20 France Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 21 Italy Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 22 Italy Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 23 Spain Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Spain Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 25 Sweden Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 26 Sweden Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 27 Norway Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 28 Norway Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 29 Denmark Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Denmark Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 31 India Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 32 India Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 33 China Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 34 China Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 35 Japan Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Japan Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 37 India Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 38 India Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 39 Australia Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 40 Australia Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 41 Thailand Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 42 Thailand Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 43 South Korea Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 44 South Korea Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 45 Brazil Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 46 Brazil Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 47 Argentina Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 48 Argentina Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 49 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 50 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 51 UAE Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 52 UAE Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 53 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 54 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, by Study Design, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Non-alcoholic Steatohepatitis Clinical Trials, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13 Global Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14 Global Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15 Global Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16 Global Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 17 Global Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 18 Global Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 19 North America Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 20 North America Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 21 North America Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 22 North America Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 23 North America Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 24 North America Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 25 US Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 26 US Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 27 US Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 28 US Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 29 US Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 30 US Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 31 US Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 36 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 38 Canada Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 44 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 46 Europe Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 47 Europe Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 48 Europe Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 49 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 50 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 51 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 52 Europe Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 53 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 54 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 55 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 56 UK Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 57 UK Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 58 UK Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 59 UK Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 60 UK Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 61 Germany Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 62 Germany Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 63 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 64 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 65 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 66 Germany Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 67 France Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 68 France Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 69 France Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 70 France Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 71 France Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 72 France Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 73 France Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 74 Italy Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 75 Italy Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 76 Italy Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 77 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 78 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 79 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 80 Italy Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 81 Spain Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 82 Spain Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 83 Spain Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 84 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 85 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 86 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 87 Spain Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 88 Denmark Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 89 Denmark Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 90 Denmark Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 91 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 92 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 93 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 94 Denmark Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 95 Sweden Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 96 Sweden Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 97 Sweden Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 98 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 99 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 100 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 101 Sweden Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 102 Norway Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 103 Norway Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 104 Norway Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 105 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 106 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 107 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 108 Norway Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 109 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 110 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 111 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 112 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 113 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 114 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 115 Asia Pacific Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 116 China Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 117 China Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 118 China Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 119 China Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 120 China Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 121 China Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 122 China Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 123 Japan Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 124 Japan Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 125 Japan Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 126 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 127 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 128 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 129 Japan Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 130 India Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 131 India Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 132 India Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 133 India Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 134 India Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 135 India Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 136 India Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 137 Australia Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 138 Australia Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 139 Australia Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 140 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 141 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 142 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 143 Australia Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 144 Thailand Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 145 Thailand Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 146 Thailand Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 147 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 148 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 149 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 150 Thailand Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 151 South Korea Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 152 South Korea Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 153 South Korea Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 154 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 155 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 156 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 157 South Korea Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 158 Latin America Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 159 Latin America Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 160 Latin America Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 161 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 162 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 163 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 164 Latin America Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 165 Brazil Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 166 Brazil Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 167 Brazil Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 168 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 169 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 170 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 171 Brazil Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 172 Argentina Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 173 Argentina Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 174 Argentina Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 175 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 176 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 177 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 178 Argentina Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 179 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 180 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 181 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 182 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 183 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 184 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 185 Middle East & Africa Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 186 South Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 187 South Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 188 South Africa Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 189 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 190 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 191 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 192 South Africa Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 193 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 194 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 195 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 196 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 197 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 198 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 199 Saudi Arabia Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 200 UAE Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 201 UAE Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 202 UAE Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 203 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 204 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 205 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 206 UAE Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 207 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 208 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 209 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 210 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 211 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 212 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig. 213 Kuwait Non-alcoholic Steatohepatitis Clinical Trials, For Expanded Access Studies, 2018 - 2030 (USD Million)